APOE and progression of AD–combining clinical and research data

Waleed Fawzi; Gayan Perera; Mizanur Khondoker; Tatjana Boitsova; Gerome Breen; Robert Stewart

doi:10.1016/j.neurobiolaging.2013.10.053

APOE and progression of AD–combining clinical and research data

Waleed Fawzi, Gayan Perera, Mizanur Khondoker, Tatjana Boitsova, Gerome Breen, Robert Stewart

Research output: Contribution to conference › Abstract › peer-review

Abstract

Cognitive decline in Alzheimer’s disease (AD) is inevitable, but the rate of this decline varies markedly between patients. Identifying a marker for the rate-of-decline can help in predicting prognosis and allocating resources and charting the course of care with patients and their families. Apolipoprotein E gene (APOE) is an important risk factor for late-onset AD and the presence of the genotype is the most significant genetic risk factor. However, establishing a role for APOE in predicting the rate of decline has proved elusive.

Original language	English
Pages	719-720
Number of pages	2
DOIs	https://doi.org/10.1016/j.neurobiolaging.2013.10.053
Publication status	Published - Mar 2014
Event	6th International Conference on Alzheimers Disease and Related Disorders in the Middle East - Istanbul, Turkey Duration: 25 Oct 2013 → 27 Oct 2013

Conference

Conference	6th International Conference on Alzheimers Disease and Related Disorders in the Middle East
Country/Territory	Turkey
Period	25/10/13 → 27/10/13

Access to Document

10.1016/j.neurobiolaging.2013.10.053

http://www.sciencedirect.com/science/article/pii/S0197458013005058

Cite this

@conference{a67f098706364e54a9020ab48358b745,

title = "APOE and progression of AD–combining clinical and research data",

abstract = "Cognitive decline in Alzheimer{\textquoteright}s disease (AD) is inevitable, but the rate of this decline varies markedly between patients. Identifying a marker for the rate-of-decline can help in predicting prognosis and allocating resources and charting the course of care with patients and their families. Apolipoprotein E gene (APOE) is an important risk factor for late-onset AD and the presence of the genotype is the most significant genetic risk factor. However, establishing a role for APOE in predicting the rate of decline has proved elusive.",

author = "Waleed Fawzi and Gayan Perera and Mizanur Khondoker and Tatjana Boitsova and Gerome Breen and Robert Stewart",

year = "2014",

month = mar,

doi = "10.1016/j.neurobiolaging.2013.10.053",

language = "English",

pages = "719--720",

note = "6th International Conference on Alzheimers Disease and Related Disorders in the Middle East ; Conference date: 25-10-2013 Through 27-10-2013",

}

TY - CONF

T1 - APOE and progression of AD–combining clinical and research data

AU - Fawzi, Waleed

AU - Perera, Gayan

AU - Khondoker, Mizanur

AU - Boitsova, Tatjana

AU - Breen, Gerome

AU - Stewart, Robert

PY - 2014/3

Y1 - 2014/3

N2 - Cognitive decline in Alzheimer’s disease (AD) is inevitable, but the rate of this decline varies markedly between patients. Identifying a marker for the rate-of-decline can help in predicting prognosis and allocating resources and charting the course of care with patients and their families. Apolipoprotein E gene (APOE) is an important risk factor for late-onset AD and the presence of the genotype is the most significant genetic risk factor. However, establishing a role for APOE in predicting the rate of decline has proved elusive.

AB - Cognitive decline in Alzheimer’s disease (AD) is inevitable, but the rate of this decline varies markedly between patients. Identifying a marker for the rate-of-decline can help in predicting prognosis and allocating resources and charting the course of care with patients and their families. Apolipoprotein E gene (APOE) is an important risk factor for late-onset AD and the presence of the genotype is the most significant genetic risk factor. However, establishing a role for APOE in predicting the rate of decline has proved elusive.

U2 - 10.1016/j.neurobiolaging.2013.10.053

DO - 10.1016/j.neurobiolaging.2013.10.053

M3 - Abstract

SP - 719

EP - 720

T2 - 6th International Conference on Alzheimers Disease and Related Disorders in the Middle East

Y2 - 25 October 2013 through 27 October 2013

ER -